With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.
To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937., 22348-32-9
As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.
Reference:
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI